OncoNOx ApS and SEED Capital today announced the formation and seed funding of a novel cancer company OncoNOx ApS. The company has developed a series of novel anti-cancer compounds, which are modifications of already approved drugs. The compounds are more potent than standard cancer chemotherapeutics in several animal models of cancer.
OncoNOx is founded by a very experienced group of scientists and biotech executives from Italy, Switzerland, USA and Denmark. Headed by Professor Ferdinando Nicoletti (Chief Scientific Officer of OncoNOx) the international group has discovered and characterized novel cancer compounds for the past 6 years.
OncoNOx has two compounds in preclinical testing for cancer: OX1001 (Saq-NO), which is an analog of the marketed protease inhibitor Saquinavir and OX27-NO, a derivative of an anti-inflammatory compound in clinical development.